The Lewin Group, a US consulting and policy analysis firm, has estimated at between $1,500.0 billion and 1,700.0 billion the cost of changing the US health care system according to President Barack Obama's election promises. However, this is likely to be an underestimate, given that spending bills going through Congress have attracted sizeable additional "earmarks," or supplementary commitments that are often unrelated to the issue being voting on. Pres Obama is reported to be considering a legislative device, the budget reconciliation process, to prevent opposition Republicans from amending or blocking the reform program.
So far, Pres Obama has committed to finding the first $634.0 billion installment, which supporters hope will lead to universal health care insurance coverage. The Pharmaceutical Research and Manufacturers of America (PhRMA) supports the President's initiative, although this may come at the cost of several measures that are detrimental to its members: patent reform; price controls imposed on Medicare Part D prescription drug purchases; the legalization of parallel trade; and a follow-on biotechnology review pathway that is unfavorable to brand-name companies (see page 13).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze